A major breakthrough in cancer immunotherapy was the discovery of immune checkpoint
proteins, which function to effectively inhibit the immune system through various mechanisms. …

… Immune checkpoint inhibitors (ICIs) are new therapeutic strategies for non-small cell lung
cancer (NSCLC). We aimed to quantitatively evaluate the efficacy and safety of ICIs in NSCLC. …

… a safety ranking of immune checkpoint inhibitor (ICI) drugs for treatment of cancer. DESIGN
… safety of immune checkpoint inhibitor (ICI) drugs in the treatment of patients with cancer …

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …

… Immune checkpoint inhibitors (ICIs) revolutionized … safety, we sought to identify the incidence,
timing, and risk factors for acute graft rejection following ICI therapy. For the clinical efficacy…

The use of immune checkpoint inhibitors (ICIs) in combination therapy is an emerging trend
in tumor immunology. However, the value of combination immunotherapy remains …

… This systematic review examined the efficacy and safety associated with immune checkpoint
inhibitors (ICIs) in patients with HCC, finding 3 randomized clinical trials eligible for meta-…

Background: Immune checkpoint inhibitors (ICI) have shown promising prospects in
gastroesophageal junction (G/GEJ) cancer immunotherapy, many clinical trials have been carried …

… Immune checkpoint inhibitor (ICI) is a revolutionary breakthrough in the field of cancer treatment.
Because of dysregulated activation of the immune … AID, the safety and efficacy of ICIs in …

… In this review and meta-analysis we evaluated the benefits of immune checkpoint inhibitors,
especially the PD-1/PD-L1 inhibitors nivolumab, pembrolizumab and atezolizumab, as a …